← Back to all signals
RESEARCH PAPER ANALYSIS

Safety and Efficacy of Romiplostim in Maintaining Chemotherapy Interval and Dose Intensity in Pediatric Patients With Solid Tumors and Chemotherapy-Induced Thrombocytopenia.

AI interpretation is pending for this paper.

Open original publication →
PMID41964555
JournalPediatric blood & cancer
Publication Date2026-04-11
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is a complication of myelosuppressive chemotherapy. Management consists of platelet transfusions, dose reductions, and delays in subsequent chemotherapy cycles, which can lead to a decrease in progression-free survival as well as overall survival in this patient population. Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that binds to and activates the TPO receptor on megakaryocyte precursors, increasing platelet production. Literature to support the routine use of romiplostim in the setting of CIT in pediatric patients is limited. OBJECTIVE: To evaluate the safety profile and efficacy of romiplostim in achieving and maintaining platelets ≥75,000/mL to allow resumption of chemotherapy without recurrence of CIT in pediatric patients with solid tumors. METHODS: This single-center retrospective chart review was conducted at a tertiary pediatric hospital. Patients ≤22 years of age were included if they received romiplostim for CIT from July 1, 2020, to December 31, 2023. The primary outcome of this study was to determine the number of patients who were responsive to romiplostim. RESULTS: A total of 18 patients were included in the analysis. Twelve patients (70%) were responsive to romiplostim. There was an average of two dose reductions prior to romiplostim initiation versus one dose reduction during treatment with romiplostim (p = 0.46) and three delays prior to versus one delay during treatment with romiplostim (p = 0.0008). Average time to platelet count of ≥75,000/µL was 30 days prior to romiplostim versus 15 days during romiplostim. CONCLUSION: Romiplostim may decrease the number of chemotherapy dose reductions and delays in pediatric patients with CIT, but further prospective studies are necessary to determine its place in therapy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Fear of Recurrence and Medication Adherence in Pediatric Leukaemia Survivors in Low-Resource Settings. Juntendo medical journal 70.8 2 Histopathologically Compatible Neurocysticercosis Mimicking an Intracranial Tumor in a Child. Iranian journal of parasitology 60.8 3 Direct medical costs of chronic diseases in Jordan: a systematic review. Health economics review 71.5 4 Panniculitis masquerading as generalised lymphadenopathy in a neonate: a diagnostic dilemma - a case report and a mini review. BMC pediatrics 49.0 5 The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes. Journal of cannabis research 81.79 6 Integrating Pediatric Dentistry Into Multidisciplinary Palliative Care for Pediatric Oral Cancer Patients: A Scoping Review. Sage open pediatrics 60.8 7 [Clinical characteristics in different age subgroups of non-pregnant young patients with papillary thyroid carcinoma]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 63.9 8 Unusual presentation of pediatric lichen planus with cutaneous, oral, and nail involvement: a case report. Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire : JCHD 49.9 9 Sex differences in gastrointestinal cancers incidence and mortality among adolescents and young adults in China: an age-period-birth cohort study. Journal of translational internal medicine 57.5 10 Diffuse brainstem gliomas across the pediatric, adolescent, and adult age spectrum: Clinical and radiological features, molecular profile, and determinants of survival in a multicenter retrospective cohort of 42 patients. Surgical neurology international 69.02 11 Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma. Communications medicine 54.9 12 Cervicothoracic intramedullary teratoma in a 6-year-old child: A case report. Surgical neurology international 45.5 13 Occipital interhemispheric transtentorial approach for microsurgical resection of a posterior fossa medulloblastoma: 2-dimensional operative video. Surgical neurology international 59.9 14 Calvarial erosion secondary to epithelioid glioblastoma: A molecularly characterized case report. Surgical neurology international 55.0 15 Longitudinal changes in bone mineral density, bone turnover markers, and body composition in children and adolescents treated for acute lymphoblastic leukemia. Frontiers in endocrinology 61.9 16 Case Report: Successful treatment of drug-resistant epilepsy with unilateral deep brain stimulation of the anterior nucleus of the thalamus. Frontiers in neuroscience 58.0 17 Surgical resection combined with TACE for primary clear cell carcinoma of the liver: a case report and literature review. Frontiers in surgery 49.9 18 Hypomorphic biallelic LIFR variants define a multisystem disorder with survival beyond infancy and hyperinflammatory vulnerability. Frontiers in immunology 61.72 19 Cancer Stem Cells in Drug Delivery Strategies: Current Advances and Future Directions. Current drug delivery 62.16 20 Calcified choroid plexus papilloma of the temporal horn presenting with seizures in an adult without hydrocephalus: An illustrative case. Surgical neurology international 59.9 21 TRIM65-BTG3-HIF-1α axis drives osteosarcoma progression via M2 macrophage polarization and angiogenesis. Journal of translational internal medicine 53.4 22 Pediatric Leptomeningeal Glial Tumors: A Retrospective Case Series and Review of the Literature. Turkish archives of pediatrics 63.3 23 Management of Obesity in Special Populations and Limited-Resource Settings: An Egyptian Medical Position Statement. Diabetes, metabolic syndrome and obesity : targets and therapy 61.9 24 Voxelwise white-matter compositional connectivity mapping from diffusion MRI via reliability-aware hierarchical inference. Medical image analysis 56.0 25 The visible and invisible scars of childhood cancer: A qualitative study of body image and identity in survivorship. British journal of health psychology 59.6 26 Cytogenetic Landscape of Complex Karyotypes Across Hematological Malignancies: Common and Disease-Specific Patterns in a Large Single-Center Cohort. Genes, chromosomes & cancer 63.7 27 Dynamics of the Prevalence of Non-communicable Diseases in the Urban Double Cotonou - Abomey-Calavi (South of Benin). The Nigerian postgraduate medical journal 38.5 28 Validation of Modified Albumin-Bilirubin-Tumor Stage as a Prognostic Model in Early-Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation. The Kaohsiung journal of medical sciences 70.5 29 A 17-cm ileocecal inflammatory myofibroblastic tumor with severe inflammatory syndrome in a child: a case report. Journal of surgical case reports 45.5 30 Giant Lipoma of the Thoracic Wall in a Two-Year-Old Girl: Imaging Features Supporting a Benign Diagnosis. Cureus 57.5 31 Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cell Transplantation Program for Patients With Hematologic Malignancy in a Resource-Limited Center in Chile. Annals of transplantation 69.1 32 Children of advanced cancer patients need better support: A case report. Palliative & supportive care 49.5
PATIENT-FRIENDLY SUMMARY

Safety and Efficacy of Romiplostim in Maintaining Chemotherapy Interval and Dose Intensity in Pediatric Patients With Solid Tumors and Chemotherapy-Induced Thrombocytopenia.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic